Drugs / DRibble vaccine
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03057340 | Jun 2017 → Dec 2019 | non-small cell lung carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT02234921 | Oct 2014 → Aug 2018 | prostate adenocarcinoma | UbiVac | Completed | No outcome recorded |
| Phase 1 | NCT00850785 | Jan 2009 → May 2012 | non-small cell lung carcinoma | Providence Health & Services | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01909752 | Jul 2013 → Nov 2016 | non-small cell lung carcinoma | UbiVac | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DRibble vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01909752 ↗ |
| Known as | DPV-001 DRibble vaccine | “DPV-001 DRibble vaccine” NCT02234921 ↗ |
| Modality | Vaccine | “Tumor-derived autophagosome vaccines (DRibbles) have the potential to broaden immune response to poorly immunogenic tumors.” PMID 29258618 ↗ Dec 2017 |
| Route | Other | “Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.” NCT02234921 ↗ |